Log in or Sign up for Free to view tailored content for your specialty!
Therapeutics/Diagnostics News
Tenofovir alafenamide maintains virological control in HBV with renal, hepatic impairment
Tenofovir alafenamide was safe and maintained virological response in patients with chronic hepatitis B virus infection and renal or hepatic impairment who switched from tenofovir disoproxil fumarate or other antivirals, according to data.
FDA expands Voquezna approval for heartburn relief in non-erosive GERD
The FDA has expanded approval for Phathom Pharmaceuticals’ Voquezna tablets 10 mg to alleviate heartburn related in non-erosive gastroesophageal reflux disease, according to a company press release.
Log in or Sign up for Free to view tailored content for your specialty!
Q&A: AI chatbot helps make colonoscopy prep ‘a little less painful’ for patients
AI has already made its mark in gastroenterology as a tool for detecting gastrointestinal lesions, adenomas and inflammatory bowel disease. However, its next phase of evolution might seem the most unlikely: Aiding colonoscopy preparation.
FDA grants orphan drug designation to pouchitis treatment derived from green tea
The FDA has granted orphan drug designation to PharmassêtX’s PSX-514, a drug derived from an active component of green tea, for the treatment of pouchitis, according to a company press release.
Q&A: Phenotype test predicting semaglutide response could ‘change conversation’ on obesity
In a Healio exclusive, Andres J. Acosta, MD, PhD, highlights data demonstrating that the MyPhenome test may serve as a biomarker to determine whether a patient with obesity will be a “good responder” to semaglutide.
Extended tofacitinib use led to ‘complete’ clinical response in refractory celiac disease
Tofacitinib “should be considered as a treatment option” for patients with refractory celiac disease type 2 who previously failed treatment with therapies such as budesonide, according to data in Clinical Gastroenterology and Hepatology.
Higher adalimumab concentration linked to complete healing in perianal fistulizing Crohn’s
An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology.
Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD
The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.
VIDEO: Larsucosterol reduces mortality by more than 50% in alcohol-associated hepatitis
In a Healio video exclusive, Mitchell L. Shiffman, MD, reports that U.S. patients with severe alcohol-associated hepatitis treated with larsucosterol experienced a “statistically significant” reduction in 90-day mortality — more than 50%.
VIDEO: Bulevirtide remains ‘efficacious, well tolerated’ in chronic hepatitis D at 2 years
In a Healio video exclusive, Anu Osinusi, MD, MPH, reported long-term bulevirtide monotherapy 2 mg and 10 mg remained safe and effective for chronic hepatitis D virus with improved biochemical, fibrosis and virologic markers at 144 weeks.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read